WithdrawnPhase 1

Hepatic Artery Infusion of CD34+ Cells

0Started 2002-05

Plain-language summary

The primary objective is to determine whether donor stem cells administered via hepatic artery infusion can produce liver cells in patients with severe hepatic dysfunction post stem cell transplantation (SCT) and the safety of this procedure. The secondary objective is to improve liver function and improve survival.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * SCT recipients with severe hepatic dysfunction (bilirubin equal to or greater than 5mg/dl) and histologically documented VOD. * The original stem cell donor must be sex-mismatched, willing and able to donate G-CSF-mobilized peripheral blood stem cells. * The patient must have complete donor chimerism. Exclusion Criteria: * Patients who do not have at least 5 x 10\^6 donor CD34+ cells/kg available for infusion. * Patients with graft versus host disease (GVHD). * Patients in whom hepatic artery infusion cannot be performed because of anatomical or technical reasons. * Patients with active hepatitis B or C.

What they're measuring

Learn if donor's cells can produce liver cells when injected directly into the liver and whether this procedure will improve liver function and survival.

Timeframe: 3 Years

Trial details

NCT IDNCT00062543

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2005-10

View on ClinicalTrials.gov More Stem Cell Transplantation trials